Literature DB >> 24343785

Interpretation of genetic variants.

Patrick R Sosnay1, Garry R Cutting.   

Abstract

Sequencing of the human genome and introduction of clinical next-generation sequencing enable discovery of all DNA variants carried by an individual. Variants may be solely responsible for disease, may contribute to disease, or may have no influence on the development of disease. Interpreting the effect of these variants upon disease is a major challenge for medicine. Although the process is still evolving, certain methods are useful in discriminating the effect of variants upon phenotype. These methods have been employed to the greatest extent in Mendelian disorders where deleterious changes in one gene can cause disease. Here, we briefly review the relative merits of these methods, with emphasis on using a comprehensive approach modelled after the analysis of variants that causes cystic fibrosis.

Entities:  

Keywords:  Genetic Variation; Genotype; Mutation Analysis; Phenotype; Population Genetics

Mesh:

Substances:

Year:  2013        PMID: 24343785      PMCID: PMC4364415          DOI: 10.1136/thoraxjnl-2013-204903

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

Review 1.  Using bioinformatics to predict the functional impact of SNVs.

Authors:  Melissa S Cline; Rachel Karchin
Journal:  Bioinformatics       Date:  2010-12-15       Impact factor: 6.937

2.  Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?

Authors:  Chee Y Ooi; Annie Dupuis; Lynda Ellis; Keith Jarvi; Sheelagh Martin; Peter N Ray; Leslie Steele; Paul Kortan; Tanja Gonska; Ruslan Dorfman; Melinda Solomon; Julian Zielenski; Mary Corey; Elizabeth Tullis; Peter Durie
Journal:  Thorax       Date:  2013-10-21       Impact factor: 9.139

3.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

4.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

5.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007.

Authors:  C Sue Richards; Sherri Bale; Daniel B Bellissimo; Soma Das; Wayne W Grody; Madhuri R Hegde; Elaine Lyon; Brian E Ward
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

6.  Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene.

Authors:  Patrick R Sosnay; Karen R Siklosi; Fredrick Van Goor; Kyle Kaniecki; Haihui Yu; Neeraj Sharma; Anabela S Ramalho; Margarida D Amaral; Ruslan Dorfman; Julian Zielenski; David L Masica; Rachel Karchin; Linda Millen; Philip J Thomas; George P Patrinos; Mary Corey; Michelle H Lewis; Johanna M Rommens; Carlo Castellani; Christopher M Penland; Garry R Cutting
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

  6 in total
  7 in total

1.  New challenges in the diagnosis and management of cystic fibrosis.

Authors:  Hara Levy; Philip M Farrell
Journal:  J Pediatr       Date:  2015-06       Impact factor: 4.406

2.  Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants.

Authors:  Danieli Barino Salinas; Patrick R Sosnay; Colleen Azen; Suzanne Young; Karen S Raraigh; Thomas G Keens; Martin Kharrazi
Journal:  J Cyst Fibros       Date:  2015-03-29       Impact factor: 5.482

3.  A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease.

Authors:  Darren M Hutt; Salvatore Loguercio; Alexandre Rosa Campos; William E Balch
Journal:  J Mol Biol       Date:  2018-06-18       Impact factor: 5.469

4.  Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy.

Authors:  Darren M Hutt; Sanjay Kumar Mishra; Daniela Martino Roth; Mads Breum Larsen; Frédéric Angles; Raymond A Frizzell; William E Balch
Journal:  J Biol Chem       Date:  2018-07-09       Impact factor: 5.157

5.  Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Authors:  H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell
Journal:  Clin Genet       Date:  2016-01-20       Impact factor: 4.438

6.  HSF4 mutation p.Arg116His found in age-related cataracts and in normal populations produces childhood lamellar cataract in transgenic mice.

Authors:  Zhe Jing; Rajendra K Gangalum; Ankur M Bhat; Yoshiko Nagaoka; Meisheng Jiang; Suraj P Bhat
Journal:  Hum Mutat       Date:  2014-07-23       Impact factor: 4.878

7.  Spatial covariance analysis reveals the residue-by-residue thermodynamic contribution of variation to the CFTR fold.

Authors:  Frédéric Anglès; Chao Wang; William E Balch
Journal:  Commun Biol       Date:  2022-04-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.